This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM). Oral lenalidomide (10 mg/day) was administered on days 1-21, and oral melphalan (0.18 mg/kg) and oral prednisone (2 mg/kg) on days 1-4 of each 28-day cycle. Thalidomide was administered at 50 mg/day or 100 mg/day on days 1-28; six cycles were administered in total. Maintenance included lenalidomide 10 mg/day on days 1-21, until unacceptable adverse events or disease progression. Aspirin (100 mg/day) was given as thromboprophylaxis. A total of 44 patients with relapsed/ refractory MM were enrolled and 75% achieved at least a partial response (PR), including 32% very good PR (VGPR) and 2% complete response (CR). The 1-year progression-free survival (PFS) was 51% and the 1-year overall survival (OS) from study entry was 72%. Grade 4 hematologic adverse events included neutropenia (18%), thrombocytopenia (7%) and anemia (2%). Grade 3 non-hematologic adverse events were infections (14%), neurological toxicity (4.5%) and fatigue (7%). No grade 3/4 thromboembolic events or peripheral neuropathy were reported. In conclusion, RMPT is an active salvage therapy with good efficacy and manageable side effects. This study represents the basis for larger phase III randomized trials.
Introduction
Multiple myeloma (MM), a malignant plasma cell disorder, accounts for approximately 1% of all malignant diseases, and 15 000 new cases are diagnosed annually in Europe. 1 The oral melphalan and prednisone (MP) combination has been the standard treatment of MM for over 30 years. [2] [3] [4] Recently, the introduction of immunomodulatory agents, such as thalidomide and lenalidomide, and the proteasome inhibitor, bortezomib, have changed the therapeutic paradigm of MM. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The combination of new drugs with conventional chemotherapy has significantly increased response rates and prolonged remission in relapsed/refractory and newly diagnosed MM patients. 10, 11, 13 Thalidomide, in combination with dexamethasone or chemotherapeutic agents, has shown additive and/or synergistic activity in vivo. [15] [16] [17] In two independent randomized studies, lenalidomide plus dexamethasone was more effective than dexamethasone alone in relapsed patients. 18, 19 In patients with newly diagnosed MM, thalidomide plus MP increased the complete response (CR) rate by approximately three times when compared with MP, and the addition of lenalidomide to MP increased the CR rate by approximately five times. [20] [21] [22] [23] Differences between lenalidomide and thalidomide activity have been shown in preclinical studies. When compared with thalidomide, lenalidomide has more antiproliferative activity against hematopoietic tumors, including myeloma cell lines and patients' cells, 24, 25 increased inhibition of tumor necrosis factora secretion from activated monocytes and increased activation of T cells and natural killer cells. 26 In contrast, thalidomide has more antiangiogenic activity than lenalidomide in human models. Both lenalidomide and thalidomide interfere with key events in the angiogenic process and activities of these drugs can be differentiated qualitatively depending on what component is studied. 27 The main adverse events after thalidomide therapy include peripheral neuropathy, constipation and venous thromboembolism, 28 whereas the adverse effects related to lenalidomide therapy are neutropenia, thrombocytopenia and thrombosis. 29 No data are available on the possible in vivo additive and/or synergistic activities of the combination of lenalidomide and thalidomide. Both drugs are administered orally, each has already shown additive and/or synergistic effects when used in combination with MP, and their association does not increase the risk of peripheral neuropathy. These observations provide the rationale for evaluating the tolerability and efficacy of the four-drug combination, that is, lenalidomide, melphalan, prednisone and thalidomide (RMPT).
Materials and methods

Patient selection
This trial was a phase II multicenter, non-comparative, openlabel study of RMPT as salvage therapy in patients with advanced MM. A total of 44 patients were enrolled at six Italian centers between May 2007 and March 2008. Patient inclusion criteria were: measurable disease, defined as a monoclonal immunoglobulin concentration on serum electrophoresis of X10 g/l immunoglobulin G or X5 g/l immunoglobulin A, or urinary excretion of monoclonal light chain X200 mg/24 h; relapse after one or two lines of previous therapy or MM refractory to salvage chemotherapy, as defined by progression during treatment or within 60 days after the completion of treatment 30 for those who had not been previously treated with thalidomide or lenalidomide in association with MP; Karnofsky performance status of X60%; platelet count of X100 Â 10 9 /l; absolute neutrophil count of X1.0 Â 10 9 /l; corrected serum calcium o3.5 mmol/l (o14 mg per 100 ml); serum hepatic aminotransferase levels of p2.5 Â the upper limit of normal; total bilirubin levels of p1.5 Â the upper limit of normal; and calculated or measured creatinine clearance levels of X20 ml/min. Exclusion criteria were: presence of another cancer, psychiatric disease, grade 2 peripheral neuropathy and hypersensitivity to thalidomide. Patients agreed to use effective contraception and women of childbearing age had to give a negative pregnancy test before enrolment.
The study was approved by the institutional review board at each participating center. All patients gave written informed consent before entering the study, which was carried out in accordance with the Declaration of Helsinki.
Sample size and outcome measures
The sample size of the study was estimated according to the Simon two-stage design for phase II clinical trials. The parameters used in the calculation of the sample size were: (1) undesirable low proportion of very good partial response (VGPR) (p0) ¼ 0.20; (2) desirable high proportion of VGPR (p1) ¼ 0.40; (3) one-sided accepted on response a ¼ 0.05 (significance level of the statistical test); and (4) type II error (b) ¼ 0.20 (corresponding to a power of 80%). With these parameters, 4/13 patients needed to achieve VGPR in the first phase of the study and at least 12/44 needed to achieve VGPR at the end of the trial to meet the primary efficacy end point. The primary safety end points were: p30% grade 4 neutropenia for 41 week or grade 4 hematological adverse event (except neutropenia), or any grade 3 non-hematological adverse event. The secondary end points were: the duration of progression-free survival (PFS) and overall survival (OS), the rate of adverse events and the relationship between responses obtained with RMPT treatment and duration of PFS.
Treatment
A total of 44 patients were enrolled in the study. For each 28-day cycle all patients received: oral lenalidomide (10 mg/ day) on days 1-21; oral melphalan (0.18 mg/kg) on days 1-4; and oral prednisone (2 mg/kg) on days 1-4. All patients also received oral thalidomide either at a dose of 50 mg/day (22 patients) or 100 mg/day (22 patients) on days 1-28. There were a total of 6 cycles of treatment ( Figure 1 ). Maintenance therapy included lenalidomide (10 mg/day) on days 1-21 of each cycle, until unacceptable adverse events or disease progression were reported. Aspirin (100 mg/day) was given as thromboprophylaxis.
The standard dose attenuation schedule for lenalidomide was 10, 7.5, 5 and 2.5 mg/day, until interruption; for thalidomide, dose reduction was 100, 50 and 50 mg/day every other day, until interruption. For patients who experienced grade 4 hematologic toxicity, except neutropenia (grade 4 neutropenia for 44 days), or grade 3/4 non-hematologic toxicity, lenalidomide and/or thalidomide were withheld until recovery from toxicities and then resumed at the next lower dose.
Pre-treatment, efficacy and safety assessments
Pre-treatment evaluations consisted of patient history and physical examination, electrocardiogram, chest radiographs and skeletal survey. Blood samples were collected at screening, during each cycle (days 1 and 15), and monthly during the maintenance phase. Two negative pregnancy tests were required for all women of childbearing potential: the first within 10-14 days of starting treatment and the second within 24 h before the start of lenalidomide and thalidomide therapy. A clinical neurologic evaluation and a thrombosis assessment were performed during the initial screening, during treatment and maintenance phases and at the end of treatment. Efficacy and safety assessments were carried out every 28 days.
Treatment responses were monitored by measurement of M-protein in serum and urine, and were defined using the uniformed response criteria of the International Myeloma Working Group. 30 In brief, a CR required disappearance of M-protein in serum and urine, and a negative M-protein immunofixation result. A VGPR required a X90% reduction of M-protein in serum, or a urine M-protein level of o100 mg/ 24 h. A partial response (PR) required an M-protein reduction of X50% in serum and X90% in urine. Stable disease was defined as responses that did not meet the criteria for CR, VGPR, PR or progressive disease (defined as an increase of X25% of M-protein from baseline values). Bone marrow plasmacytosis, skeletal disease and serum calcium were included in the response evaluation.
PFS was calculated from the time of enrolment until the date of progression, relapse or the date the patient was last known to be in remission. OS was calculated from the time of enrolment until the date of death or the date the patient was last known to be alive. All adverse events were assessed at each visit and were graded according to the National Cancer Institute Common Terminology Criteria (version 3). 31 Causes of death were recorded as attributable to MM, study drugs, other causes or a combination of these.
Statistical analysis
Time-to-event analyses were assessed using the Kaplan-Meier method. 32 The P-values were calculated with log-rank. The incidence of adverse events was compared using the w 2 test or 
Results
Patients
At the time of the analysis, all 44 patients enrolled in the study received at least one cycle of therapy and were evaluated. A total of 26 patients received RMPT as second-line therapy and 18 as third-line therapy. The median time between initial treatment for MM and the first administration of RMPT was 43.5 months (range 2-160 months); of all patients enrolled, four subjects had relapsed/refractory disease. Baseline patient demographics and other characteristics are listed in Table 1 . The median number of cycles administered was five (range 1-6).
A total of 22 patients did not complete the assigned six cycles of therapy; reasons included disease progression (n ¼ 9), withdrawal of consent (n ¼ 4) and adverse events (n ¼ 9). Adverse events leading to discontinuation were: pneumonia (n ¼ 1), septic shock (n ¼ 1), sudden death not disease related (n ¼ 1) and grade 3/4 hematologic toxicity (n ¼ 6). A total of 22 patients entered the maintenance phase. Of these, one patient died before starting maintenance therapy because of meningitis and another patient stopped maintenance therapy because of progressive disease. Of 44 patients, 9 had the dose of lenalidomide and/or thalidomide reduced without subsequent discontinuation. The reasons for dose reduction were neurologic toxicities (n ¼ 5), fatigue (n ¼ 1), hematologic toxicity (n ¼ 2) and infection (n ¼ 1). The lenalidomide dose was reduced in one patient, the thalidomide dose in four patients and both lenalidomide and thalidomide were reduced in four patients. The median time to first dose reduction was 3 months.
Efficacy
A significant proportion (34%) of patients had VGPR or better, and 75% (33/44) of patients achieved a PR or better ( Table 2) . Of the 44 patients, CR was achieved in 1 patient and VGPR was achieved in 14 patients. In patients who received RMPT with thalidomide 100 mg/day, CR plus VGPR were reported in 41% (9/22) of patients; PR was reported in 36% (8/22) of patients.
The median duration of follow-up from study entry was 11.4 months (range 1-21 months) for survivors. Progression, relapse or death occurred in 48% (21/44) of RMPT patients. The 1-year PFS was 51.5% in all patients (Figure 2a ) and the 1-year OS rate from the start of therapy among all patients was 72% (Figure 2b) . Overall, 10 patients died during the study; 6 because of disease progression and 4 because of adverse events. By exploratory subgroup analysis, the 1-year PFS was significantly improved in patients who achieved at least a VGPR compared with patients achieving a PR only (P ¼ 0.03). The 1-year PFS among patients who received RMPT as second-line therapy was not statistically significant when compared with patients who received RMPT as third-line therapy (P ¼ 0.3). The 1-year PFS rate in patients with deletion of chromosome 13 (n ¼ 11) when compared with patients without deletion of chromosome 13 (n ¼ 6) was not statistically significant (30 versus 55%, respectively; P ¼ 0.34). The 1-year PFS was 60% in 5 patients with translocation (4;14) and was not reached in 12 patients without (P ¼ 0.03).
Safety
The most common grade 1/2 adverse events were constitutional symptoms (fever 25% and fatigue 43%), gastrointestinal (45%), Table 1 Baseline patient and disease characteristics (n ¼ 44) RMPT for relapsed/refractory MM A Palumbo et al
neurologic (36%), metabolic (16%) and infective events (23%).
Only one patient experienced a deep-vein thrombosis episode (grade 1). Grade 1/2 adverse events were typically mild to moderate and were manageable with routine support. The most common grade 3 adverse events were neutropenia (45%), anemia (32%), thrombocytopenia (27%), pneumonia (7%), fatigue (7%) and febrile neutropenia (4.5%). Grade 4 adverse events included neutropenia (18%), thrombocytopenia (7%) and infection (7%). No patient had grade 3/4 peripheral neuropathy or grade 3/4 thromboembolic events (Table 3) . Three patients died because of infection (pneumonia, septic shock and meningitis), and one patient died of sudden death not disease related. During treatment with RMPT, 12 patients needed transfusion support, 17 received granulocyte colonystimulating factor and 21 received recombinant human erythropoietin. Transfusion requirement decreased from the first to the last cycle, from 9 to 0 patients.
The majority of grade 3/4 hematologic adverse events occurred during the first three cycles of therapy (29 events during cycles 1-3 versus 8 events during cycles 4-6), and in those patients who received RMPT as the third-line therapy compared with second-line therapy. Treatment with thalidomide 100 mg did not significantly increase hematologic and extra-hematologic toxicity.
Discussion
In this phase II multicenter, open-label, non-comparative study, we evaluated the safety and efficacy profiles of RMPT in patients with relapsed/refractory MM. The rates of at least VGPR and PR were 34 and 75%, respectively, and the 1-year PFS in all patients was 51.5%.
In three independent phase III studies in newly diagnosed elderly MM patients, the combination of MP with thalidomide (MPT) showed VGPR or better rates of 47, 20 37 21 and 21%, 22 respectively. In newly diagnosed MM patients, the combination of MP plus lenalidomide gave a VGPR or better rate of 48%. 23 In relapsed/refractory MM patients, MPT induced a near CR rate of 12%, 33 the RMPT regimen reported a VGPR rate of 34%. In advanced MM, the combination of MPT plus bortezomib (VMPT) induced an VGPR or better rate of 43%. 34 CR and VGPR are important surrogates of patient outcome and the high proportion of responses observed after treatment with RMPT are encouraging. Despite the use of a combination that included two immunomodulatory agents, the association between thalidomide and lenalidomide with MP seems to increase the response rates observed with MPT and MP plus lenalidomide. [20] [21] [22] [23] In RMPT patients, the VGPR rate was higher in patients receiving thalidomide 100 mg/day versus those receiving thalidomide 50 mg/day, but these data should be considered with caution, as the sample size of the two groups was not large enough to reach statistical significance.
The present study is the first in vivo study in which the standard MPT combination was combined with a new immunomodulatory drug, lenalidomide. In preclinical studies, thalidomide showed more antiangiogenesis activities, whereas lenalidomide showed more immunomodulatory effects. [24] [25] [26] [27] As no data are available on the possible in vivo additive and/or synergistic activities of the combination of two immunomodulatory drugs, the association of lenalidomide with thalidomide is empirical. Our hypothesis was that the two immunomodulatory drugs could reinforce the quality of response, with an additive positive effect, without excessive toxicity. As the major limiting factor with a combination of bortezomib and thalidomide is peripheral neuropathy, the RMPT regimen substituted bortezomib with lenalidomide, as this agent lacks neurological toxicity, and no patient experienced grade 3/4 peripheral neuropathy. RMPT for relapsed/refractory MM A Palumbo et al
Half patients did not complete the assigned six cycles of therapy, mainly because of disease progression and adverse events, including infective complications and grade 3/4 hematologic toxicity. Myelosuppression, particularly neutropenia, was the most common high-grade toxicity reported in phase III trials including lenalidomide. 18, 19 Combining lenalidomide and thalidomide seems to increase hematologic toxicity when compared with single immunomodulatory agent therapy.
Neutropenia was the most common hematologic adverse event. Although the use of thalidomide monotherapy is not associated with significant hematologic toxicity, this study showed that addition of lenalidomide enhanced myelosuppression. In this study, the incidences of grade 3 and 4 neutropenia were 45 and 18%, respectively, whereas in the VMPT study they were 23 and 20%, respectively. 34 The incidences of grade 3 and 4 infections were 14 and 7%, respectively, whereas in the VMPT study grade 3 infection was 16% and no grade 4 infections were reported. 34 In another study that included a combination of bortezomib, melphalan, dexamethasone and thalidomide, 3 patients of 62 (5%) had fatal infections. 35 In the present study, early deaths occurred in 4/44 patients (9%), mainly because of infection. The combination of two immunomodulatory agents may increase the risk of infections in comparison with other regimens that include a proteasome inhibitor or an immunomodulatory drug. In the present study, only one episode of grade 1 deep-vein thrombosis occurred with aspirin (100 mg/day) thromboprophylaxis. These data do not show any increase in the incidence of deep-vein thrombosis and they are consistent with previous studies, which show that relapsed/refractory MM patients seem to have a lower risk of deep-vein thrombosis in comparison with patients with newly diagnosed MM. 36 RMPT was a well-tolerated regimen even in patients with abnormal renal function and a creatinine clearance level of 30-50 ml/min. In these patients, no significant increases in neutropenia or thrombocytopenia were reported, but the dose of lenalidomide was only 10 mg/day and creatinine clearance was 430 ml/min in all patients. Conventional and fluorescence in situ hybridization-based cytogenetic analyses are used to assess the risk level, with the future aim of influencing choice of therapy. In our study, patients with translocation (4;14) had a shorter 1-year PFS when compared with patients who did not have this abnormality. The prognostic value and effect of these abnormalities remain to be fully defined and, particularly in our study, one of the major limitations is the small sample size (44 patients) and the availability of fluorescence in situ hybridization in only 17 of 44 patients.
Whether sequential single-agent treatment with less toxicity would be preferable in comparison with more complex combinational regimens remains an important but unanswered question. A combination approach might be considered at diagnosis when there is the best chance to induce a prolonged remission duration. A sequential approach with a less intensive regimen should be considered during subsequent relapses, when the risk of toxicity is increased and when more palliative approaches may be suggested.
Different factors should be considered in determining an appropriate therapy for relapsed MM patients. A variety of combinations containing different new drugs are now available, and they lead to very interesting results. This scheme could be a further option of treatment even in the era of new drugs and could be proposed to patients who relapsed after new drugs or as a re-challenge of drugs previously administered in monotherapy. RMPT could also be proposed when a suboptimal response or treatment resistance emerges and a further intensification of therapy is required. Being an oral therapy, RMPT could be preferred for patients who cannot make frequent clinic visits for intravenous therapy. In conclusion, salvage therapy with RMPT induces significant responses in patients with relapsed/refractory MM. Further randomized trials are needed to evaluate the ability of this combination to improve on the current MPT standard of care at diagnosis.
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